drugset / Trial / NCT05830240
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Phase 0
Unknown
9 enrolled
Shanghai Yunying Medical Technology
Eye & ENT Hospital of Fudan University · collab
NaSingle-groupOpen-labelTreatment
Summary
9 participants are expected to be enrolled for this open，single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory head and neck cancer.
Timeline
- Start
- 2023-03-27
- Primary completion
- 2025-03-27
- Completion
- 2026-03-27